(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 March 2012 (22.03.2012)

PCT

(10) International Publication Number
WO 2012/035519 A1

(51) **International Patent Classification**:
A61K 39/385 (2006.01) *A61P 31/04* (2006.01)

(21) **International Application Number**:
PCT/IB2011/054069

(22) **International Filing Date**:
16 September 2011 (16.09.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/383,668 16 September 2010 (16.09.2010) US
1101665.6 31 January 2011 (31.01.2011) GB

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BERTI, Francesco** [IT/IT]; Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **CONTORNI, Mario** [IT/IT]; Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **COSTANTINO, Paolo** [IT/IT]; Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **FINCO, Oretta** [IT/IT]; Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **GRANDI, Guido** [IT/IT]; Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **MAIONE, Domenico** [IT/IT]; Novartis Vaccines, Via Fiorentina 1, I-53100 Siena (IT). **TELFORD, John** [GB/IT]; Novarits Vaccines, Via Fiorentina 1, I-53100 Siena (IT).

(74) **Agent**: **MARSHALL, Cameron, John**; Carpmaels & Ransford, One Southampton Row, London WC1B 5HA (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/035519 A1

(54) **Title**: IMMUNOGENIC COMPOSITIONS

(57) **Abstract**: The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype la conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype lb conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof.